ASMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Assembly Biosciences Inc (ASMB) is not a strong buy at this moment for a beginner, long-term investor. Despite positive catalysts such as hedge fund interest and a bullish analyst rating, the financial performance shows significant net income and EPS declines. Additionally, the technical indicators and options data do not provide a clear buy signal. The lack of recent news or significant congress trading data further reduces the urgency to invest immediately.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 52.93, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock closed below the pivot level of 29.347, indicating potential resistance. Key support is at 28.345, and resistance is at 30.348.
Hedge funds are increasing their buying activity significantly (161.98% increase). Analysts have raised the price target from $39 to $43, citing strong clinical results for ABI-5366 and ABI-1179.
The company's net income and EPS have dropped significantly YoY (-313.74% and -182.28%, respectively). No recent news or congress trading data is available to provide additional support for a buy decision.
In Q4 2025, revenue increased by 477.26% YoY to $42.47M, but net income dropped by -313.74% YoY to $22.09M. EPS also declined by -182.28% YoY to 1.3. Gross margin remained stable at 100%.
Guggenheim raised the price target to $43 from $39 and maintained a Buy rating, citing strong clinical results and increased enthusiasm for key drug candidates.
